BGB-A317: Phase I started

BeiGene began an open-label, Australian Phase I trial of BGB-A317 plus oral BGB-290 in 124 patients with advanced solid tumors. Part A of the trial will evaluate escalating doses of the compounds until the maximum tolerated dose (MTD)/recommended Phase II dose is determined. The dose-expansion part B will enroll 100 patients with tumors carrying breast cancer 1 early onset (BRCA1) or BRCA2 mutations or with documented homologous recombination or mismatch repair deficiency. ...